Trends in treatment of newly treated schizophrenia-spectrum disorder patients in taiwan from 1999 to 2006

Pharmacoepidemiology and Drug Safety

Volumn 21, Issue 9, 2012, Pages 989-996

  Wu, Chi Shin ^a   Lin, Yu Ju ^a   Feng, Jung ^a  

^a FAR EASTERN MEMORIAL HOSPITAL   (Taiwan)

Author keywords

Antipsychotics; Schizophrenia; Trend

Indexed keywords

ANTIDEPRESSANT AGENT; ARIPIPRAZOLE; BENZODIAZEPINE; HALOPERIDOL; MOOD STABILIZER; QUETIAPINE; RISPERIDONE; SULPIRIDE;

ADULT; ANXIETY DISORDER; ARTICLE; COMORBIDITY; DRUG USE; FEMALE; FOLLOW UP; HEALTH CARE UTILIZATION; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MOOD DISORDER; PATIENT COMPLIANCE; PRESCRIPTION; PRIORITY JOURNAL; SCHIZOPHRENIA; SLEEP DISORDER; TAIWAN;

ADULT; ANTIPSYCHOTIC AGENTS; DATABASES, FACTUAL; DRUG THERAPY, COMBINATION; HUMANS; LOGISTIC MODELS; LONGITUDINAL STUDIES; MALE; MEDICATION ADHERENCE; MENTAL HEALTH SERVICES; MIDDLE AGED; MULTIVARIATE ANALYSIS; PHYSICIAN'S PRACTICE PATTERNS; PSYCHOTROPIC DRUGS; SCHIZOPHRENIA; STATISTICS, NONPARAMETRIC; TAIWAN; TIME FACTORS; YOUNG ADULT;

EID: 84865866133     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.3254     Document Type: Article

References (37)

1. World Health Organization. The Global Burden of Disease. 2004 Update. http://www.who.int/healthinfo/global_burden_disease/2004_report_update/en/index.html
2. Gaebel W, Weinmann S, Sartorius N, Rutz W, McIntyre JS. Schizophrenia practice guidelines: international survey and comparison. Br J Psychiatry 2005; 187: 248-255.
3. Gilmer TP, Dolder CR, Lacro JP, et al. Adherence to treatment with antipsychotic medication and health care costs among Medicaid beneficiaries with schizophrenia. Am J Psychiatry 2004; 161: 692-699.
4. Centorrino F, Goren JL, Hennen J, Salvatore P, Kelleher JP, Baldessarini RJ. Multiple versus single antipsychotic agents for hospitalized psychiatric patients: case-control study of risks versus benefits. Am J Psychiatry 2004; 161: 700-706.
5. Yang M, Barner JC, Lawson KA, et al. Antipsychotic medication utilization trends among Texas veterans: 1997-2002. Ann Pharmacother 2008; 42: 1229-1238.
6. Chakos MH, Glick ID, Miller AL, et al. Baseline use of concomitant psychotropic medications to treat schizophrenia in the CATIE trial. Psychiatr Serv 2006; 57: 1094-1101.
7. Novick D, Bousono M, Suarez D, et al. Use of concomitant medication with antipsychotic treatment in outpatients with schizophrenia: results from the European Schizophrenia Outpatients Health Outcomes (SOHO) study. Prog Neuropsychopharmacol Biol Psychiatry 2005; 29: 972-982.
8. Citrome L, Goldberg JF, Stahl SM. Toward convergence in the medication treatment of bipolar disorder and schizophrenia. Harv Rev Psychiatry 2005; 13: 28-42.
9. Leucht S, Corves C, Arbter D, Engel RR, Li C, Davis JM. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 2009; 373: 31-41.
10. Moore TA, Buchanan RW, Buckley PF, et al. The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2006 update. J Clin Psychiatry 2007; 68: 1751-1762.
11. Edlinger M, Hausmann A, Kemmler G, et al. Trends in the pharmacological treatment of patients with schizophrenia over a 12year observation period. Schizophr Res 2005; 77: 25-34.
12. Rothbard AB, Kuno E, Foley K. Trends in the rate and type of antipsychotic medications prescribed to persons with schizophrenia. Schizophr Bull 2003; 29: 531-540.
13. Chien IC, Chou YJ, Lin CH, Bih SH, Chou P, Chang HJ. Prevalence and incidence of schizophrenia among national health insurance enrollees in Taiwan, 1996-2001. Psychiatry Clin Neurosci 2004; 58: 611-618.
14. Wu CS, Lin YJ, Liu SK. Benzodiazepine use among patients with schizophrenia in taiwan: a nationwide population-based survey. Psychiatr Serv 2011; 62: 908-914.
15. Wu CS, Ting TT, Wang SC, Chang IS, Lin KM. Effect of benzodiazepine discontinuation on dementia risk. Am J Geriatr Psychiatry 2011; 19: 151-159.
16. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987; 40: 373-383.
17. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992; 45: 613-619.
18. WHO Collaborating Centre for Drug Statistic Methodology. Guidelines for ATC Classification and DDD Assignment. WHO: Oslo, 2009.
19. Schemper M. Non-Parametric Partial Association Revisted. J Roy Stat Soc D-Sta 1991; 40: 73-76.
20. Clark RE, Bartels SJ, Mellman TA, Peacock WJ. Recent trends in antipsychotic combination therapy of schizophrenia and schizoaffective disorder: implications for state mental health policy. Schizophr Bull 2002; 28: 75-84.
21. Stahl SM, Buckley PF. Negative symptoms of schizophrenia: a problem that will not go away. Acta Psychiatr Scand 2007; 115: 4-11.
22. Dolder CR, Lacro JP, Dunn LB, Jeste DV. Antipsychotic medication adherence: is there a difference between typical and atypical agents? Am J Psychiatry 2002; 159: 103-108.
23. Soares BG, Fenton M, Chue P. Sulpiride for schizophrenia. Cochrane Database Syst Rev 2000; 2: CD001162.
24. Wang J, Omori IM, Fenton M, Soares B. Sulpiride augmentation for schizophrenia. Cochrane Database Syst Rev 2010; 1: CD008125.
25. Ganguly R, Kotzan JA, Miller LS, Kennedy K, Martin BC. Prevalence, trends, and factors associated with antipsychotic polypharmacy among Medicaid-eligible schizophrenia patients, 1998-2000. J Clin Psychiatry 2004; 65: 1377-1388.
26. Correll CU, Rummel-Kluge C, Corves C, Kane JM, Leucht S. Antipsychotic combinations vs monotherapy in schizophrenia: a meta-analysis of randomized controlled trials. Schizophr Bull 2009; 35: 443-457.
27. Al-Zakwani IS, Barron JJ, Bullano MF, Arcona S, Drury CJ, Cockerham TR. Analysis of healthcare utilization patterns and adherence in patients receiving typical and atypical antipsychotic medications. Curr Med Res Opin 2003; 19: 619-626.
28. Wolkowitz OM, Pickar D. Benzodiazepines in the treatment of schizophrenia: a review and reappraisal. Am J Psychiatry 1991; 148: 714-726.
29. Green MF. Cognitive impairment and functional outcome in schizophrenia and bipolar disorder. J Clin Psychiatry 2006; 67: e12.
30. Liu SK, Chiu CH, Chang CJ, Hwang TJ, Hwu HG, Chen WJ. Deficits in sustained attention in schizophrenia and affective disorders: stable versus state-dependent markers. Am J Psychiatry 2002; 159: 975-982.
31. Citrome L, Levine J, Allingham B. Changes in use of valproate and other mood stabilizers for patients with schizophrenia from 1994 to 1998. Psychiatr Serv 2000; 51: 634-638.
32. Siris SG. Depression in schizophrenia: perspective in the era of "Atypical" antipsychotic agents. Am J Psychiatry 2000; 157: 1379-1389.
33. Caceres MC, Penas-Lledo EM, de la Rubia A, Llerena A. Increased use of second generation antipsychotic drugs in primary care: potential relevance for hospitalizations in schizophrenia patients. Eur J Clin Pharmacol 2008; 64: 73-76.
34. The Department of Health, Executive Yuan, R.O.C.(Taiwan). http://www.doh.gov.tw/CHT2006/DM/DM2_2.aspx?now_fod_list_no=10144&class_no=440&level_no=4 [January 13, 2012].
35. Norman RM, Malla AK, Manchanda R, Harricharan R, Takhar J, Northcott S. Social support and three-year symptom and admission outcomes for first episode psychosis. Schizophr Res 2005; 80: 227-234.
36. Addington DE, Beck C, Wang J, et al. Predictors of admission in first-episode psychosis: developing a risk adjustment model for service comparisons. Psychiatr Serv 2010; 61: 483-488.
37. Faraone SV, Chen WJ, Goldstein JM, Tsuang MT. Gender differences in age at onset of schizophrenia. Br J Psychiatry 1994; 164: 625-629.